We are proud to announce that the GensuApp, the application which we developed together with MiyaHealth for people with diabetes, has obtained ISO 13845:2016 certification and the CE mark. Thus, GensuApp officially gains the status of a Class I medical device in Europe. GensuApp is an application software comprising of a mobile application for patients and a web portal for doctors and nurses.

As Jeremy Launders, CEO of BIOTON, emphasizes, artificial intelligence will never replace qualified doctors and nurses. However, it can be an invaluable aid in the daily management of diabetes for both patients and therapeutic teams. Based on data entered into the application, GensuApp aims to improve the quality of life for people with diabetes and ensure their safety. To make it easier for patients to use the application, it includes a virtual assistant feature.

The application allows the user to:

  • monitor glycemia by synchronizing with a Bluetooth-enabled glucometer, or entering the test result manually
  • record measurements related to weight, physical activity, and healthy eating,
  • share data with their attending physician,
  • expand their knowledge on diabetes-related topics through rich educational resources.

Founded in 2019, MiyaHealth builds and operates digital infrastructure that powers healthcare. The company offers three product suites, namely MiyaPayor, MiyaPatient, and MiyaProvider, all of which leverage MiyaHealth’s AI and ML data capture, processing, and interoperability capabilities across the healthcare ecosystem. MiyaHealth’s technologies enable Payors and Providers to do more with less, and offer patients a better healthcare experience.

“This partnership supports the course of our patient’s treatment and management of their conditions, ultimately leading to better outcomes. Managing diabetes can be challenging due to the numerous tasks required to achieve optimal glycaemic control. We have customised GensuApp with MiyaHealth to provide a comprehensive overview, offering patients and doctors real-time data to empower them to make better immediate decisions. Being the first of its kind in Poland, the GensuApp will allow us to support a wider network of people with diabetes. During our pilot programs, we have received excellent feedback from our patients” – says Jeremy Launders.

We are proud that we will be able to o put a certified medical device in the hands of people with diabetes and therapeutic teams, which, using state-of-the-art technologies, will support them in their daily challenges and increase their safety and comfort.